News

MBF Bioscience Announces the Acquisition of Vidrio Technologies

MBF Bioscience, a leading provider of bioscience image analysis tools, announced that it has completed the acquisition of Vidrio Technologies. Terms of the transaction were not disclosed.

Based in Ashburn, VA, Vidrio is a fast-growing provider of software and hardware components for laser scanning and two photon microscopes.

“Vidrio Technologies builds widely loved tools for researchers who utilize two photon and laser scanning microscopes to answer some of the toughest questions in biology,” says MBF Bioscience Founder and President Jack Glaser. “They have assembled a truly special team of engineers and I am thrilled that MBF will have the opportunity to be a part of the continued development, release, and support of Vidrio’s impressive products.”

“The team at Vidrio couldn’t be more excited to be joining forces with MBF,” says Vidrio Technologies CEO Bruce Kimmel. “We have grown rapidly in recent years and MBF’s large development team will be a great resource for us as we continue to invest in the development of industry-leading tools for bioscience researchers.”

Georg Jaindl, Senior Software Engineer at Vidrio Technologies said, “Vidrio has a pipeline full of exciting new products that we can’t wait to show our customers. By joining forces with MBF, we will be able to build these tools for our customers faster and provide even more responsive technical support than our customers already receive.”

Recent News

04/17/2024

U.S. Department of Health and Human Services Awards Kaléo with Contract to Develop Next Generation Organophosphate Nerve Agent Poisoning Countermeasure

Kaléo, a privately-held U.S. pharmaceutical company today announced their selection by the Biomedical Advanced Research and Development Authority (BARDA), part of Administration for Strategic Preparedness and Response (ASPR) within the U.S. Department of Health and Human Services (HHS), to develop the latest generation pralidoxime chloride auto-injector as a countermeasure against organophosphate or nerve agent poisoning.

04/15/2024

Activation Capital Welcomes Dr. Jim Pannucci as its Vice President of Entrepreneurship

Activation Capital, an innovation ecosystem development organization, announced today that it has appointed Jim Pannucci, Ph.D., PMP as its Vice President of Entrepreneurship. As the new Vice President of Entrepreneurship, Dr. Pannucci will help Activation Capital continue to grow a deep talent base of life sciences entrepreneurs operating in the region and help empower them

04/10/2024

Phlow kicks off drug ingredient production in Petersburg

A local pharma company and player in a regional effort to build a pharmaceutical hub in Central Virginia has started manufacturing operations. Richmond-based Phlow Corp. recently began manufacturing ingredients used in medicines at a facility at 2818 N. Normandy Drive in Petersburg, according to Robby Demeria, the company’s chief corporate affairs officer. The 19,200-square-foot facility